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Now that the Obama administration has begun to reshape
and restore the government, the editors of Genome
Medicine have asked our opinions on the future of
biomedical research in the United States. As we have
previously noted, we do not see one another as seers or
soothsayers nor are we particularly trained to understand
what might be called biopolitical economics. With those
caveats we offer the following.
Barack Obama is blowing a breath (indeed a fresh breeze) of
clean air through the political and emotional tendrils of the
United States. A battered US electorate and the rest of the
world have survived (albeit barely) the George W Bush
administration, and, though all of us are bloodied, we
remain unbowed. Now we can gaze upon our new and vastly
exciting president who seems to combine high intelligence
with political skills. He will need every skill in the book to
face the challenges before him, the nation and the world.
For those of us in science, and particularly genome medicine,
the future remains shakily optimistic. Obama obviously
supports science, but the nation’s economy (and indeed the
world’s economy) is in tatters. Despite the obvious hazards,
we feel confident that Obama will approach the economy,
general science and our own focused area of medicine with
analytical and creative forcefulness. He has already demon-
strated his interest and commitment by the appointments
that he has made thus far. The top science advisors are
absolutely first rate, and we could not ask for better bio-
medicine advisors than Harold Varmus and Eric Lander. So
the tea leaves seem to be settling favorably. Indeed, the new
funding for the National Institutes of Health (NIH) within
the new economic stimulus legislation is a harbinger of far
better support for biomedical science by this administration.
But the challenges that we face are enormous. The NIH, the
major support mechanism for biomedical science in the
United States, is encumbered by systemic problems that
have gone unresolved for decades. The clumsiness and
waste inherent in the NIH budgeting system become
intolerable when the economy is disrupted and the so-called
discretionary budget of the federal government is severely
jeopardized. Money that could advance genome-based
medical research is now being shoveled into the insatiable
maws of huge and totally irresponsible banks that hide the
money, refuse to lend it, give their incompetent officers
bonuses and decorate their offices. Even a perfectly run
NIH or any other useful federal agency would starve in a
setting in which such vast amounts of tax-payer money are
diverted into emergency funding of the economy.
The banking system notwithstanding, those of us who are
devoted to genome medicine and its future must honestly
deal with our own problems and help this president to help
our field. Our first actions must be self-critical because we
are part of the problem. After all, the NIH is really us. We
serve on the study sections and advisory councils that make
the funding decisions. If NIH is failing the next generation
of investigators (and fundable priority scores are presently
very difficult to achieve) we have to be certain that every
penny of NIH expenditure truly supports the future of
biomedical science.There are at least five major intrinsic problems that inhibit
NIH productivity. These include highly dispersed leadership,
non-competitive compensation for top scientists and
leaders, demands from pressure groups and their congres-
sional representatives for support of research in one disease
at the expense of others, a high priced but essential
intramural program (the scientific effort on the NIH
campus) that has lost some of the luster of its halcyon days
and, above all, an annual budgeting process that vastly
inhibits rational long-term planning. NIH staggers along
with these systemic inhibitors when times are good and
administrations are friendly. In the face of economic disaster
and/or an administration that cares little for the agency,
NIH begins to crumble. During the past eight years, the NIH
has been protected by a Bush administration error. Given
their record in other departments, it is likely that the Bush
crowd intended to appoint an incompetent director of the
institute, but they made a rare mistake. They chose Elias
Zerhouni, a careful, responsible and totally decent man who
helped the institutes to survive. In fact professional NIH
administrators have labored honorably under very difficult
circumstances and deserve credit for doing so at a time
during which both intra- and extramural morale have been
very poor. Obama’s first act must be to find an excellent
director and give that person the authority to run the ship.
We hope that the new director will focus on individual
initiatives and put somewhat less emphasis on hugely
expensive consortium grants that usually have a low
outcome for the money. We believe that Obama will make an
excellent selection. But the intrinsic weaknesses that have
dogged the NIH for so long must also be addressed now if
these all-important institutes are to flourish in the face of
grave funding shortages and the inflation that will surely
follow our current fiscal profligacy. Somehow, NIH must be
allowed to pursue long-term budget planning instead of the
usual annual ‘use it or lose it’ approach that inevitably leads
to a surfeit of applications in good years and terrible
fundable priority scores in poor ones.
As members of a grateful and devoted scientific community
and as individuals committed to the future of genome
medicine, we stand ready to help the Obama administration
in any way we can. We know that their intentions are
honorable and intelligent, and we strongly suspect that they
realize that economic investment in NIH-funded biomedical
research will gain a better return on the dollar than bailout
schemes for failing companies that did not develop new
technologies fast enough to compete in the global market.
Biomedical research has proved to be an effective economic
engine in several states in this country, so why not invest in
this area as a priority in rebuilding our economy? To act on
those decisions, the Obama administration will need the
support and cooperation of the entire scientific establishment.
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